Metabolic marker group for diagnosing coronary heart disease
A metabolic marker, coronary heart disease technology, applied in the field of biochemistry, to improve the convenience of diagnosis, accurate and reliable results, and promote standardization
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0026] Example 1: Screening and characterization of plasma differential metabolites between patients with coronary heart disease and patients without coronary heart disease (including normal coronary arteries and patients with coronary atherosclerosis)
[0027] 1. Objects and methods
[0028] 1. The source of the specimen
[0029] After obtaining the consent of the patients, the peripheral venous blood plasma of 480 patients with coronary atherosclerosis, 867 patients with coronary heart disease and 350 patients with normal coronary arteries in Jiangsu Provincial People's Hospital from September 2010 to June 2015 were collected. Normal coronary arteries were confirmed by coronary angiography. The age and sex of normal coronary artery patients were matched with patients with coronary atherosclerosis and coronary heart disease. All patients with coronary atherosclerosis, coronary heart disease and normal coronary arteries have normal heart, lung, liver, kidney and hematopoieti...
Embodiment 2
[0053] Example 2: Construction of ROC curves to compare the ability of 6 differential metabolites to diagnose patients with coronary heart disease and non-coronary heart disease (including normal coronary arteries and coronary atherosclerosis)
[0054] Receiver operating curve (ROC) method was used for verification, and the expression levels of differential metabolites in the plasma of patients with coronary heart disease and non-coronary heart disease (including normal coronary arteries and coronary atherosclerosis) were used to judge its use in the diagnosis of coronary heart disease Ability. The results showed that six differential metabolites, citramalic acid, methionine, taurine, malic acid, phenylalanine, and linoleic acid, were used individually to diagnose and distinguish patients with coronary heart disease from those with normal coronary arteries and those with coronary heart disease. The ability to compare with patients with coronary atherosclerosis is strong, and t...
Embodiment 3
[0070] Embodiment 3: application in the screening treatment or the medicine of alleviating coronary heart disease
[0071] The blood plasma of 185 patients with coronary heart disease before and after the drug treatment was detected, and the results showed that: with the increase of the course of drug treatment, the patient's condition was gradually relieved, and the levels of the 6 metabolic markers provided by the present invention in the plasma gradually tended to It is at the level of normal coronary arteries, and there is no significant difference (P>0.05) between the plasma levels of normal coronary arteries after complete cure. This result is consistent with the detection results of coronary angiography. Therefore, the metabolic markers provided by the present invention can be used to screen drugs for treating or alleviating coronary heart disease.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com